The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas

Inclusion Criteria

• •1. Pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma.
• •2. Consider immunotherapy or combined immunotherapy based on clinical judgement.
• •3. Signed and dated informed consent form.
• •4. Commitment to comply with research procedures and co-operation in the implementation of the full research process.
• •5. Aged 6-80 years old.